BBOT insider transaction filings
BridgeBio Oncology Therapeutics, Inc. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-14. Screen BBOT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Chen Bihua — Director, 10% owner | 1 | — | — | 4 |
| Cobo Marc — Principal Accounting Officer | 2 | — | — | 4 |
| Beltran Pedro — President and CEO, Director | 1 | — | — | 1 |
| Ben Yong — Chief Med & Dev Officer | 1 | — | — | 1 |
| Elmelech Idan — COO & Principal Financial Ofcr | 1 | — | — | 1 |
Recent Form 4 filings — BridgeBio Oncology Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-14 | 4 | Cobo Marc — Principal Accounting Officer | Grant/award (A): 9,038 @ $0 · Tax withholding (F): 203 @ $5.52 · Grant/award (A): 43,700 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Elmelech Idan — COO & Principal Financial Ofcr | Tax withholding (F): 343 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Ben Yong — Chief Med & Dev Officer | Tax withholding (F): 1,047 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Beltran Pedro — President and CEO, Director | Tax withholding (F): 1,047 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Cobo Marc — Principal Accounting Officer | Tax withholding (F): 125 @ $7.80 | EDGAR |
| 2026-07-06 | 4 | Chen Bihua — Director, 10% owner | Other (J): 4,528,186 @ $0 · Other (J): 2,692,459 @ $0 · Other (J): 1,704,862 @ $0 · Other (J): 130,865 @ $0 | EDGAR |
| 2026-06-18 | 4 | Lebowitz Peter F — Director | Grant/award (A): 7,289 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Kelleher Raymond J. — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Tipirneni Praveen P. — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Kumar Neil — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Bauer Jake — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Chen Bihua — Director, 10% owner | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | MCCORMICK FRANK — Director | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-05-12 | 4 | Elmelech Idan — COO & Principal Financial Ofcr | Grant/award (A): 758,222 (derivative) @ $0 | EDGAR |
| 2026-05-12 | 4 | Beltran Pedro — President and CEO, Director | Grant/award (A): 1,103,837 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Ben Yong — Chief Med & Dev Officer | Tax withholding (F): 1,047 @ $9.03 | EDGAR |
| 2026-05-05 | 4 | Beltran Pedro — President and CEO, Director | Tax withholding (F): 1,047 @ $9.03 | EDGAR |
| 2026-05-05 | 4 | Mehra Uneek | Tax withholding (F): 524 @ $9.03 | EDGAR |
| 2026-03-26 | 4 | Lebowitz Peter F — Director | Grant/award (A): 63,350 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | Mehra Uneek — Chief Financial Officer | Grant/award (A): 23,330 @ $0 · Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | Beltran Pedro — Chief Scientific Officer | Grant/award (A): 46,670 @ $0 · Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | Ben Yong — Chief Med & Dev Officer | Grant/award (A): 46,670 @ $0 · Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Grant/award (A): 1,114,400 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Disposition to issuer (D): 1,114,400 (derivative) | EDGAR |
| 2025-10-16 | 4 | BridgeBio Pharma LLC — 10% owner BridgeBio Pharma, Inc. — 10% owner | Other (J): 784,720 | EDGAR |
| 2025-10-06 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Grant/award (A): 1,614,400 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Beltran Pedro — Chief Scientific Officer | Grant/award (A): 357,177 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Ben Yong — Chief Med & Dev Officer | Grant/award (A): 357,177 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Mehra Uneek — Chief Financial Officer | Grant/award (A): 633,570 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Tipirneni Praveen P. — Director | Grant/award (A): 52,269 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Wallace Eli M. — Chief Executive Officer, Director | Grant/award (A): 499,731 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Bauer Jake — Director | Grant/award (A): 138,193 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | MCCORMICK FRANK — Director | Grant/award (A): 91,076 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | Chen Bihua — Director, 10% owner | Option exercise (M): 4,172,126 · Disposition to issuer (D): 152,940 @ $0 · Grant/award (A): 760,496 @ $10.72 · Grant/award (A): 639,110 @ $10.72 · Grant/award (A): 5,598,425 @ $10.72 · Grant/award (A): 1,905,046 · +4 more | EDGAR |
| 2025-08-11 | 4 | Obradovic Nebojsa — Chief Legal Officer | Holdings only — no transactions reported | EDGAR |
| 2025-08-11 | 4 | Tripp Caleb — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2025-08-11 | 4 | Holman Albert A III | Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | McKenna Mark C. | Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Schmid John P. | Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — BridgeBio Oncology Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BBOT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →